NHS decisions on approving medicines are a carefully crafted process, ensuring only the most effective and safe treatments make it onto the shelves. A recent briefing from the House of Commons Library sheds light on this intricate system, involving several key organisations that work together to evaluate new drugs before they can be prescribed to patients across the UK.
The journey begins with licensing by the Medicines and Healthcare products Regulatory Agency (MHRA), assessing a drug's safety, quality, and efficacy. However, this licence does not automatically guarantee NHS availability – further evaluation is conducted by bodies such as NICE in England and Wales, the Scottish Medicines Consortium (SMC) in Scotland, and the All Wales Medicines Strategy Group (AWMSG) in Wales.
These organisations play a vital role in determining the cost-effectiveness and clinical benefit of new treatments. For instance, NICE develops national guidance and recommendations on medicines, assessing whether a drug provides sufficient health benefits to justify its cost to the NHS through a rigorous appraisal process, considering evidence from clinical trials, patient perspectives, and the wider impact on healthcare services.
Following a positive recommendation from NICE or its devolved equivalents, NHS England and other commissioning bodies generally fund the medicine. However, there can be further negotiations with pharmaceutical companies regarding drug prices, particularly for high-cost treatments – an ongoing challenge in ensuring patient access to innovative medicines while managing NHS resources.
The process also considers specialised commissioning arrangements for rare diseases or highly complex treatments, which fall under specific pathways within NHS England. This ensures that niche medications with high costs can be evaluated and potentially funded if they meet strict criteria for patient benefit and value.